GlassScriptPhysician profile
John A Koontz
NPI 1881666071
$7,227.34
in general payments reported to CMS, 2019-2025
39 companies · $1,462 in 2025
The $1,462 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,066 · 2020: $1,154 · 2021: $360 · 2022: $854 · 2023: $1,354 · 2024: $979 · 2025: $1,462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,794.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,794.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,091.39 | 2019-2025 | Wegovy, Ozempic |
| Astrazeneca Pharmaceuticals LP | $1,084.65 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $721.09 | 2019-2025 | |
| Abbvie INC. | $592.84 | 2020-2025 | |
| Lilly USA, LLC | $576.02 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $363.11 | 2019-2024 | Veozah, Myrbetriq |
| Amgen INC. | $291.91 | 2019-2025 | Evenity, Prolia, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $278.92 | 2020-2025 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $277.92 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $268.43 | 2019-2025 | Trintellix |
| Exact Sciences Corporation | $188.35 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $178.27 | 2019-2023 | Belsomra |
| Abbott Laboratories | $141.98 | 2021-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $115.90 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $95.10 | 2022-2025 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Koontz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.